SCHEMBL23928207

SCHEMBL23928207

CCNc1ccc(CCNC(=O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CNR1 P21554 3/20 0.47
FFAR1 O14842 1/20 0.46
KDM4E B2RXH2 1/20 0.46
F13A1 P00488 1/20 0.46
KMT2A Q03164 2/20 0.45
GLA P06280 1/20 0.45
MAPT P10636 2/20 0.45
PLAAT3 P53816 2/20 0.44
PLAAT5 Q96KN8 2/20 0.44
PLAAT2 Q9NWW9 2/20 0.44
PLAAT4 Q9UL19 2/20 0.44
HPGD P15428 1/20 0.44
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
ALOX12 P18054 1/20 0.43
EPHX1 P07099 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23928122 0.82 CNR1 (0.49) NPC1RAB9ASMN1; SMN2CNR1KDM4E
SCHEMBL4511148 0.82 KDM4E (0.52) NPC1RAB9ASMN1; SMN2KDM4EF13A1
SCHEMBL23291226 0.81 MAPT (0.48) NPC1RAB9ASMN1; SMN2CNR1FFAR1
SCHEMBL23928193 0.81 HRH3 (0.50) NPC1RAB9ACNR1FFAR1KDM4E
SCHEMBL28255137 0.80 CNR1 (0.46) NPC1RAB9ASMN1; SMN2CNR1FFAR1
SCHEMBL4584283 0.80 NPC1 (0.64) NPC1RAB9ASMN1; SMN2CNR1KDM4E
SCHEMBL23291264 0.79 NAMPT (0.57) NPC1RAB9ASMN1; SMN2KMT2AGLA
SCHEMBL23135379 0.78 ADRA2A (0.45) KDM4EF13A1KMT2AMAPTALDH1A1
SCHEMBL6184546 0.78 CNR1 (0.49) NPC1RAB9ASMN1; SMN2CNR1KMT2A
SCHEMBL20541797 0.77 GRIN1 (0.56) SMN1; SMN2KDM4EKMT2AHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ADORA2A, ADORA1, ADORA3 NPC1 1520/4885RAB9A 2869/4885SMN1; SMN2 4178/4885
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 NPC1 1520/4885RAB9A 2869/4885SMN1; SMN2 4178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.